Drug Trial Radar · NCT07174726
A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
Last checked: Nov 20, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Sep 10, 2025
Primary completion
Dec 31, 2029
Study completion Dec 30, 2030
Sponsor
- Lead sponsor
- Beacon TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Sep 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 12 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 2 Study is to see if the investigational study drug, laruparetigene zovaparvovec, also known as AGTC-501, given in both eyes, is safe and works to preserve and/or improve vision and other symptoms of XLRP.
Conditions
- X-Linked Retinitis Pigmentosa (XLRP)
Interventions
Adeno-associated virus vector expressing a human RPGR geneBiological
Male participants 12-50 years of age treated by subretinal injection with the dose of AGTC-501
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number and percentage of participants experiencing Grade 3 or higher ocular or non-ocular treatment-emergent adverse events (TEAEs), including treatment-emergent serious adverse events (SAEs), at Month 12Time frame: Day 0 - Month 12
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
University of Florida Jacksonville Ophthalmology
Jacksonville, Florida
Bascom Palmer Eye Institute
Miami, Florida
Duke Eye Center
Durham, North Carolina
Cincinnati Eye Institute
Cincinnati, Ohio
OHSU Casey Eye Institute
Portland, Oregon
Retina Foundation of the Southwest
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.